Category Archives: TRIPS

Canadian generic drugmakers find fault with USMCA

Source: Pharmaletter 3rd Oct 2018, New Delhi The pharmaceutical intellectual property aspects of the United States-Mexico-Canada Agreement (USMCA), which was agreed on Monday to replace the former North American Free Trade Agreement (NAFTA) accord, have come in for criticism from the … Continue reading

Posted in Biologics/Biosimilars, Data Exclusivity, USMCA | Leave a comment

Indian Civil Society letter on TB Declaration negotiations -UN High Level Meeting

To, Mr. Narendra Modi, Prime Minister of India Mr. J. P. Nadda, Health Minister Ms. Sushma Swaraj, Foreign Minister Mr. Suresh Prabhu, Commerce Minister Date: 31st July 2018 Sub: Asking India to support TRIPS flexibilities in UN High Level Meeting on TB … Continue reading

Posted in Access to Medecines, Delinkage, R&D, TRIPS, TRIPS flexibilities, Tuberculosis (TB), Uncategorized | Leave a comment

Here’s the short note on UNHLM on TB and US pressurising to dilute TRIPS flexibilities

The United Nations is going to hold a High Level Meeting on TB in New York in September. The member countries of UN will sign on a declaration will set the direction in which work on TB, globally, will move. … Continue reading

Posted in TRIPS, TRIPS flexibilities, Tuberculosis (TB), US Pressure | Leave a comment

The grounds for opposing patent applications for velpatasvir

Source: MSF | July 09, 2018 Gilead Sciences has applied for multiple patents on oral hepatitis C medicines – sofosbuvir and velpatasvir in India: not only limiting itself to basic patents but also staking claims on a number of additional … Continue reading

Posted in Patent linkage, Patent Opposition, Patent Term Extension, Patents | Leave a comment

The problem with high drug prices isn’t ‘foreign freeloading,’ it’s the patent system

by Tahir Amin, CNBC | June 27, 2018 One in four Americans are unable to fill prescriptions due to high prices. Today’s drug patent monopolies are stronger than at any point in the last century, raising prescription prices. Until the … Continue reading

Posted in Evergreening, Patent, Patent examination system, Patent Opposition, Uncategorized | Leave a comment

Document exclusivity weakens Norwegian pandemic preparedness

Source: Dagens Medisin | June 20, 2018 IMAGINE THAT A large global o, break of contagious disease also includes Norway, such as a new flu-like disease with high risk of transmission and mortality. Imagine that there is only one effective drug, … Continue reading

Posted in Compulsory Licensing, Patent, Patents | Leave a comment

WIPO: Proposal to amend PCT Regulations undermines TRIPS flexibilities

Geneva, 15 June (TWN) – A proposal to amend a treaty regulation at the World Intellectual Property Organization (WIPO) will compromise TRIPS flexibilities, especially in relation to the scope of patentability for national patent offices. The International Bureau (i.e. WIPO … Continue reading

Posted in Patent, TRIPS, TRIPS flexibilities, TRIPS plus, TRIPS&IP rights, Uncategorized, WIPO | Leave a comment